The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Long Acting Beta Agonist-Global Market Insights and Sales Trends 2024
Synopsis
Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.
The global Long Acting Beta Agonist market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Long Acting Beta Agonist in various end use industries. The expanding demands from the Hospitals, Clinics, Ambulatory Surgical Center and Others, are propelling Long Acting Beta Agonist market. Liquid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tablet segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Long Acting Beta Agonist market, driven by demand from China, the second largest economy with some signs of stabilising, the Long Acting Beta Agonist market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Long Acting Beta Agonist, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Long Acting Beta Agonist market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Long Acting Beta Agonist market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Long Acting Beta Agonist sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Long Acting Beta Agonist covered in this report include Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva and Merck, etc.
The global Long Acting Beta Agonist market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck
Global Long Acting Beta Agonist market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Long Acting Beta Agonist market, Segment by Type:
Liquid
Tablet
Global Long Acting Beta Agonist market, by Application
Hospitals
Clinics
Ambulatory Surgical Center
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Long Acting Beta Agonist companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.
The global Long Acting Beta Agonist market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Long Acting Beta Agonist in various end use industries. The expanding demands from the Hospitals, Clinics, Ambulatory Surgical Center and Others, are propelling Long Acting Beta Agonist market. Liquid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tablet segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Long Acting Beta Agonist market, driven by demand from China, the second largest economy with some signs of stabilising, the Long Acting Beta Agonist market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Long Acting Beta Agonist, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Long Acting Beta Agonist market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Long Acting Beta Agonist market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Long Acting Beta Agonist sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Long Acting Beta Agonist covered in this report include Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva and Merck, etc.
The global Long Acting Beta Agonist market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck
Global Long Acting Beta Agonist market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Long Acting Beta Agonist market, Segment by Type:
Liquid
Tablet
Global Long Acting Beta Agonist market, by Application
Hospitals
Clinics
Ambulatory Surgical Center
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Long Acting Beta Agonist companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Long Acting Beta Agonist
1.1 Long Acting Beta Agonist Market Overview
1.1.1 Long Acting Beta Agonist Product Scope
1.1.2 Long Acting Beta Agonist Market Status and Outlook
1.2 Global Long Acting Beta Agonist Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Long Acting Beta Agonist Market Size by Region (2018-2029)
1.4 Global Long Acting Beta Agonist Historic Market Size by Region (2018-2023)
1.5 Global Long Acting Beta Agonist Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Long Acting Beta Agonist Market Size (2018-2029)
1.6.1 North America Long Acting Beta Agonist Market Size (2018-2029)
1.6.2 Europe Long Acting Beta Agonist Market Size (2018-2029)
1.6.3 Asia-Pacific Long Acting Beta Agonist Market Size (2018-2029)
1.6.4 Latin America Long Acting Beta Agonist Market Size (2018-2029)
1.6.5 Middle East & Africa Long Acting Beta Agonist Market Size (2018-2029)
2 Long Acting Beta Agonist Market by Type
2.1 Introduction
2.1.1 Liquid
2.1.2 Tablet
2.2 Global Long Acting Beta Agonist Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Long Acting Beta Agonist Historic Market Size by Type (2018-2023)
2.2.2 Global Long Acting Beta Agonist Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Long Acting Beta Agonist Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Long Acting Beta Agonist Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Long Acting Beta Agonist Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Long Acting Beta Agonist Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Long Acting Beta Agonist Revenue Breakdown by Type (2018-2029)
3 Long Acting Beta Agonist Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Center
3.1.4 Others
3.2 Global Long Acting Beta Agonist Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Long Acting Beta Agonist Historic Market Size by Application (2018-2023)
3.2.2 Global Long Acting Beta Agonist Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Long Acting Beta Agonist Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Long Acting Beta Agonist Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Long Acting Beta Agonist Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Long Acting Beta Agonist Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Long Acting Beta Agonist Revenue Breakdown by Application (2018-2029)
4 Long Acting Beta Agonist Competition Analysis by Players
4.1 Global Long Acting Beta Agonist Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Long Acting Beta Agonist as of 2022)
4.3 Date of Key Players Enter into Long Acting Beta Agonist Market
4.4 Global Top Players Long Acting Beta Agonist Headquarters and Area Served
4.5 Key Players Long Acting Beta Agonist Product Solution and Service
4.6 Competitive Status
4.6.1 Long Acting Beta Agonist Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Sumitomo Dainippon Pharma
5.1.1 Sumitomo Dainippon Pharma Profile
5.1.2 Sumitomo Dainippon Pharma Main Business
5.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Products, Services and Solutions
5.1.4 Sumitomo Dainippon Pharma Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.1.5 Sumitomo Dainippon Pharma Recent Developments
5.2 AstraZeneca
5.2.1 AstraZeneca Profile
5.2.2 AstraZeneca Main Business
5.2.3 AstraZeneca Long Acting Beta Agonist Products, Services and Solutions
5.2.4 AstraZeneca Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca Recent Developments
5.3 GlaxoSmithKline
5.3.1 GlaxoSmithKline Profile
5.3.2 GlaxoSmithKline Main Business
5.3.3 GlaxoSmithKline Long Acting Beta Agonist Products, Services and Solutions
5.3.4 GlaxoSmithKline Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.3.5 Boehringer Ingelheim International Recent Developments
5.4 Boehringer Ingelheim International
5.4.1 Boehringer Ingelheim International Profile
5.4.2 Boehringer Ingelheim International Main Business
5.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Products, Services and Solutions
5.4.4 Boehringer Ingelheim International Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.4.5 Boehringer Ingelheim International Recent Developments
5.5 Mylan
5.5.1 Mylan Profile
5.5.2 Mylan Main Business
5.5.3 Mylan Long Acting Beta Agonist Products, Services and Solutions
5.5.4 Mylan Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.5.5 Mylan Recent Developments
5.6 Teva
5.6.1 Teva Profile
5.6.2 Teva Main Business
5.6.3 Teva Long Acting Beta Agonist Products, Services and Solutions
5.6.4 Teva Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.6.5 Teva Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Long Acting Beta Agonist Products, Services and Solutions
5.7.4 Merck Long Acting Beta Agonist Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
6 North America
6.1 North America Long Acting Beta Agonist Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Long Acting Beta Agonist Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Long Acting Beta Agonist Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Long Acting Beta Agonist Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Long Acting Beta Agonist Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Long Acting Beta Agonist Market Dynamics
11.1 Long Acting Beta Agonist Industry Trends
11.2 Long Acting Beta Agonist Market Drivers
11.3 Long Acting Beta Agonist Market Challenges
11.4 Long Acting Beta Agonist Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
